Torrent-JB Chemicals Rs 25,689 Crore Merger Under CCI Lens Over Monopoly Concerns
- byDoctor News Daily Team
- 14 October, 2025
- 0 Comments
- 0 Mins

New Delhi:The Competition Commission of India (CCI) has expressed serious concerns over the proposed merger between Torrent Pharmaceuticals and JB Chemicals, warning that the deal could create a dominant market position and reduce competition in critical therapeutic segments. According to Zee Business report, sources familiar with the matter disclosed that the antitrust regulator has asked both companies to provide detailed information on product overlaps and market shares, with particular scrutiny on two drug categories: Nifedipine, used to treat hypertension, and Lactobacillus, a widely used probiotic. Analysts indicate that in these segments, the combined market share could reach 70–90% post-merger. Earlier, the Teamhad reported that Torrent Pharmaceuticals Limited, in collaboration with global investment firm KKR, announced that Torrent has entered into definitive agreements to acquire a controlling stake in J. B. Chemicals and Pharmaceuticals from KKR at an Equity Valuation of Rs 25,689 crores (on a fully diluted basis), followed by a merger of the two entities. The transaction marked a significant step in Torrent’s ambition to create a future-ready, diversified healthcare platform combining a deep chronic segment heritage with emerging international CDMO capabilities. Officials warn that such concentration could distort pricing, restrict competition, and give the merged entity undue control over supply, negatively impacting smaller companies and patients. However, to address regulatory concerns, both Torrent Pharma and JB Chemicals have proposed a three-year price freeze on these medicines. The CCI has issued a notice under Section 29(1) of the Competition Act, initiating a detailed investigation into the merger’s potential anti-competitive effects. The regulator will determine the next steps after reviewing the companies’ submissions. Industry observers note that this move is part of the CCI’s heightened scrutiny of pharmaceutical mergers, aimed at preventing market dominance and protecting consumer interests, reportsZee Business.
Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at
admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our
Terms of Use,
Privacy Policy, and
Advertisement Policy.
For further details, please review our
Full Disclaimer.
Recent News
NMC approves 2,337 new PG medical seats for NEET P...
- 22 October, 2025
Rajasthan MBBS student airlifted from Kazakhstan a...
- 22 October, 2025
NEET SS 2025 now on December 26th, 27th: NBE
- 22 October, 2025
Daily Newsletter
Get all the top stories from Blogs to keep track.
0 Comments
Post a comment
No comments yet. Be the first to comment!